| P/E (FY) | 32.0 | Sales (TTM) | $142.4M |
| Earnings (TTM) | $7.9M | ROE | 11.54% |
| Net Margin | 4.62% | ROIC | 9.62% |
| Debt / Equity | 0.34 | TD / EBITDA | 0.78 |
| EPS Growth 3Y | — | Sales Growth 3Y | 9.28% |
| Market Cap | $200.2M | Trading Days | 4662 |
| 52W High | 11.04 |
| 52W Low | 5.43 |
| % Off High | −10.14% |
| YTD | 10.59% | 1Y | 68.14% |
| 3Y | −3.97% | 5Y | −46.20% |
| 10Y | 208.07% | Since incept. (ann.) | 5.37% |
Patient Services And Device Solutions 59% · Patient Services 41%
| Ann. Volatility (1Y) | 55.23% | Ann. Volatility (3Y) | 52.38% |
| Sharpe (1Y) | 1.22 | Sharpe (3Y) | 0.24 |
| Max Drawdown (1Y) | −31.17% | Max Drawdown (3Y) | −58.22% |
| Beta (3Y, vs SPY) | 1.55 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ANIK | Anika Therapeutics, Inc. | $201.6M | — |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| LUCD | Lucid Diagnostics Inc. | $185.7M | — |
| KRMD | KORU Medical Systems, Inc. | $184.2M | — |
| PDEX | PRO DEX INC | $179.9M | 21.1 |
| UTMD | UTAH MEDICAL PRODUCTS INC | $225.9M | 20.4 |
| OBIO | Orchestra BioMed Holdings, Inc. | $231.1M | — |
| APYX | Apyx Medical Corp | $161.6M | — |
| PROF | Profound Medical Corp. | $263.4M | 5.1 |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $264.7M | — |
| TLSI | TriSalus Life Sciences, Inc. | $265.9M | — |
| OSUR | ORASURE TECHNOLOGIES INC | $276.8M | — |
